Drug updated on 11/15/2023
| Dosage Form | Injection (intravenous; 240 mg of nivolumab and 80 mg of relatlimab per 20 mL (12 mg and 4 mg per mL)) |
| Drug Class | Monoclonal antibodies |
| System | Multiple |
Indication
- For the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Opdualag (nivolumab and relatlimab) Prescribing Information. | 2022 | Bristol-Myers Squibb Company Princeton, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis. | 2023 | European Journal of Cancer |
| Comparative efficacy and safety of immune checkpoint inhibitors for unresectable advanced melanoma: A systematic review and network meta-analysis. | 2023 | International Immunopharmacology |
Ongoing and completed studies: ClinicalTrials.gov